AzTrials
AzTrials

Acute Kidney InjuryNCT07760129

Erector Spinae Oxygen Saturation and AKI After OPCAB

An observational study of Acute Kidney Injury and Coronary Artery Disease, run by Yonsei University.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Acute kidney injury (AKI) is a frequent and serious complication after cardiac surgery, including off-pump coronary artery bypass (OPCAB). Because AKI is diagnosed on the basis of serum creatinine, which rises 1 to 2 days after the actual renal insult, early detection and timely intervention remain difficult. Read more about this study

Who is it for?
Ages 19 years and older
What is being tested?
Near-infrared spectroscopy monitoring of erector spinae muscle and renal regional oxygen saturation
Type of treatment
Medical device
How many people
138 participants
Where
No sites listed yet
Study dates
1 Oct 2026to 31 Dec 2029
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Consecutive adult patients (19 years of age or older) scheduled for elective off-pump coronary artery bypass surgery at Severance Hospital, a tertiary university hospital in Seoul, Republic of Korea, who provide written informed consent. After consent, ultrasonography performed in the operating room before anesthetic induction measures the depth from the skin to the erector spinae muscle at the level of the left renal hilum; only patients in whom this depth is less than 2.0 cm, so that a reliable near-infrared spectroscopy signal can be obtained, are finally enrolled. Patients requiring emergency or concomitant surgery, those with severe renal impairment (estimated glomerular filtration rate below 30 mL/min/1.73 m2), previous kidney transplantation, left renal disease or a solitary kidney, a body mass index above 30 kg/m2, cardiogenic shock or mechanical circulatory support, or active bleeding or infection are not eligible.

Who may be able to join

  • Adults aged 19 years or older scheduled for elective off-pump coronary artery bypass (OPCAB) surgery.
  • Able to receive a full explanation of the purpose and procedures of the study and to provide written informed consent voluntarily.
  • Depth from the skin to the erector spinae muscle at the level of the left renal hilum, measured by ultrasonography in the operating room before anesthetic induction, of less than 2.0 cm, so that stable near-infrared spectroscopy measurement is considered feasible. Consenting patients who do not meet this criterion are not enrolled and are classified as screen failures.

Who cannot join

  • Emergency surgery.
  • Concomitant surgery performed by another department.
  • Preoperative or postoperative cardiogenic shock, or need for mechanical circulatory support.
  • Estimated glomerular filtration rate below 30 mL/min/1.73 m2.
  • Previous kidney transplantation.
  • Left renal disease or a solitary kidney.
Show all 10Show fewer
  • Body mass index above 30 kg/m2.
  • Active bleeding or active infection.
  • Inability to read and voluntarily consent to the informed consent document (for example, because of illiteracy, language barrier, or cognitive impairment).
  • Refusal to participate in the study.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Seo Hee Ko, Professor contact

+82-2-2095-9678

shk0207@yuhs.ac

About this study

Official title: Erector Spinae Muscle Oxygen Saturation as an Early Predictor of Acute Kidney Injury in Patients Undergoing Off-Pump Coronary Artery Bypass Surgery

Acute kidney injury (AKI) is a frequent and serious complication after cardiac surgery, including off-pump coronary artery bypass (OPCAB). Because AKI is diagnosed on the basis of serum creatinine, which rises 1 to 2 days after the actual renal insult, early detection and timely intervention remain difficult. Near-infrared spectroscopy (NIRS) allows non-invasive and continuous measurement of regional tissue oxygen saturation, but the effective penetration depth of commercially available devices is only approximately 2 to 2.5 cm. In most adults the renal cortex lies deeper than this, so the signal obtained from a flank sensor may originate largely from the abdominal wall musculature rather than from renal parenchyma. This limitation may explain the inconsistent association between renal regional oxygen saturation (renal rSO2) and AKI reported so far.

The erector spinae muscle at the level of the renal hilum lies within 2 cm of the skin in most patients and is supplied by the lumbar arteries and by vessels adjacent to the renal hilum. Erector spinae muscle regional oxygen saturation (ESrSO2) may therefore provide a technically more reliable NIRS signal that reflects perfusion of a vascular territory close to that of the kidney, particularly during the transient low cardiac output state induced by mechanical displacement of the heart for coronary anastomosis during OPCAB.

Read more

This single-center prospective observational cohort study will enroll 138 adult patients scheduled for elective OPCAB at Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea. ESrSO2 and renal rSO2 will be measured continuously with an INVOS oximeter from before anesthetic induction until the end of surgery, in addition to cerebral rSO2, which is part of standard care at the participating institution. The ESrSO2 and renal rSO2 channels will be physically masked on the monitor display during surgery, no alarms will be set for these two channels, and their values will not be used for any intraoperative clinical decision. The recorded data will be extracted after surgery using the INVOS Analytics Tool. Apart from placement of the additional NIRS sensors and a brief pre-induction ultrasound measurement of tissue depth, no study-specific procedure, laboratory test, or imaging study will be performed, and all anesthetic, surgical, and postoperative care will follow the standard institutional protocol.

The primary objective is to identify which ESrSO2-derived variable best predicts postoperative AKI, defined by the Kidney Disease: Improving Global Outcomes (KDIGO) criteria within 7 days after surgery. The candidate variables are the baseline value, the intraoperative nadir, the area under the threshold (AUT), and the duration under the threshold below absolute values of 60%, 55%, and 50% and below 80% of the baseline value, calculated separately for the period before cardiac displacement and for the cardiac displacement period. Secondary objectives are to assess whether the selected ESrSO2 variable provides independent and incremental predictive information beyond a pre-specified baseline risk model, to compare the predictive performance of ESrSO2 with that of cerebral rSO2 and renal rSO2, and to evaluate the prediction of severe AKI (KDIGO stage 2 to 3) and persistent AKI (lasting 48 hours or longer).

If ESrSO2 proves to be a useful early marker of AKI, it could allow real-time, non-invasive identification of patients at high risk during surgery and provide a basis for future trials of renal protective strategies.

Read the detailed description

STUDY DESIGN Single-center, prospective, observational cohort study conducted at Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea. There is no group allocation, no randomization, and no blinding of treatment. All participants receive the same standard anesthetic, surgical, and postoperative care regardless of study participation.

PARTICIPANTS AND SCREENING Adults aged 19 years or older scheduled for elective off-pump coronary artery bypass (OPCAB) are approached on the day before surgery. Written informed consent is obtained by an investigator in a private counseling room, with at least 3 hours allowed for consideration before consent is signed. After arrival in the operating room, willingness to participate is reconfirmed and, before anesthetic induction, ultrasonography is performed with the patient temporarily placed in the lateral decubitus position to measure the depth from the skin to the erector spinae muscle and to the renal cortex at the level of the left renal hilum. Only participants in whom the skin-to-erector spinae muscle depth is less than 2.0 cm, so that a stable NIRS measurement is considered feasible, are finally enrolled. Participants who do not meet this criterion are classified as screen failures, no sensor is applied, and no further study data are collected.

MEASUREMENTS NIRS sensors are applied over the left erector spinae muscle at the renal hilum level and over the ipsilateral renal cortex. Regional oxygen saturation is recorded continuously with an INVOS oximeter (Medtronic, Minneapolis, MN, USA), which is already installed in all operating rooms of the institution; no additional monitoring equipment is introduced for the study. Baseline values are recorded before anesthetic induction while the participant breathes room air. Recording continues until the end of surgery. The start and the end of mechanical displacement of the heart (from the deep pericardial stitch to heart return) are tagged as events, so that the period before cardiac displacement and the cardiac displacement period can be analyzed separately. The area under the threshold (AUT), defined as the integral of the magnitude and duration of desaturation below a given threshold, and the duration under the threshold are computed with the INVOS Analytics Tool Software.

OBSERVATIONAL INTEGRITY ESrSO2 and renal rSO2 are collected for research purposes only. The corresponding channel displays are physically masked during surgery, no alarms are set for these channels, and the values are not available to the clinical team and are not used for intraoperative or postoperative management. Data are retrieved after surgery from the device. Cerebral rSO2 remains part of standard institutional monitoring for OPCAB and is used and managed as usual.

DATA COLLECTED Preoperative: demographics, comorbidities, medications, New York Heart Association class, Canadian Cardiovascular Society class, EuroSCORE II, Society of Thoracic Surgeons risk score, hemodynamic variables, complete blood count and chemistry including serum creatinine, estimated glomerular filtration rate and serum albumin, echocardiography, and coronary angiography. All of these are part of the routine preoperative work-up for OPCAB and none are performed additionally for the study.

Intraoperative: ESrSO2, renal rSO2, cerebral rSO2, bispectral index, anesthesia and operation time, timing of cardiac displacement, ischemic time for anastomosis, arterial, pulmonary arterial and central venous pressures, heart rate, cardiac index, mixed venous oxygen saturation, rhythm, vasopressor and inotrope use, fluids, transfusion, cell saver volume, and urine output.

Postoperative: daily maximum serum creatinine for 7 days, fluid balance and transfusion for 48 hours, bleeding, urine output, use of continuous renal replacement therapy, hemodynamic and respiratory variables, mechanical ventilation and reintubation, intensive care unit and hospital length of stay, reoperation, intensive care unit readmission, complications according to the Society of Thoracic Surgeons definitions, days alive and out of hospital at 30 days, 30-day readmission, in-hospital and 30-day mortality, AKI by KDIGO criteria, and major adverse kidney events at 30 days.

DEFINITION OF AKI AKI is defined according to the KDIGO criteria as an increase in serum creatinine of 0.3 mg/dL or more within 48 hours, an increase to 1.5 times or more of the baseline value within 7 days, or urine output of less than 0.5 mL/kg/h for 6 hours.

SAMPLE SIZE The incidence of AKI after OPCAB at the participating institution is approximately 25%, and the reported predictive performance of cerebral oximetry for AKI corresponds to an area under the receiver operating characteristic curve (AUROC) of approximately 0.68. Assuming a target AUROC of 0.80 for ESrSO2 and a 95% confidence interval of 0.70 to 0.90, the Hanley and McNeil method yields a minimum required sample size of 124 participants. Allowing for approximately 10% attrition, the target enrollment is 138 participants.

STATISTICAL ANALYSIS Continuous variables are compared with the independent t test or the Mann-Whitney U test according to normality and are presented as mean with standard deviation or as median with interquartile range. Categorical variables are compared with the chi-square test or the Fisher exact test and are presented as number with percentage. A two-sided p value below 0.05 is considered significant, with Bonferroni correction for multiple comparisons. Analyses are performed with R software.

For the primary objective, receiver operating characteristic curves are constructed for each ESrSO2 variable and AUROC values are compared to identify the variable with the highest predictive performance.

For the secondary objectives, this study is explicitly framed as a pilot and exploratory study and does not aim to derive or validate a definitive prediction model. Given the expected number of AKI events and the resulting constraint on events per variable, adjustment variables are pre-specified on the basis of clinical importance and previous OPCAB-AKI literature, namely age, preoperative renal function (baseline estimated glomerular filtration rate or chronic kidney disease), diabetes mellitus, and hypoalbuminemia. These four variables are not re-tested for significance in this cohort but are fixed as an established background risk model and combined into a single linear predictor. The only term formally tested is the ESrSO2 variable, which is added to the pre-specified baseline model as an incremental term. Firth penalized logistic regression with bootstrap internal validation is used to reduce small-sample bias. Improvement in discrimination is assessed with the DeLong test for the difference in AUROC, and clinical usefulness is explored with decision curve analysis (net benefit). Reclassification indices are not used. The predictive performance of ESrSO2, cerebral rSO2, and renal rSO2 is compared in the same way, and the same approach is applied to severe AKI (KDIGO stage 2 to 3) and persistent AKI (lasting 48 hours or longer).

WITHDRAWAL AND DISCONTINUATION Participants are discontinued if conversion to on-pump coronary artery bypass occurs, if a ventricular assist device is inserted, if cardiopulmonary resuscitation or another emergency situation occurs, if continuous ESrSO2 measurement becomes technically impossible, or if consent is withdrawn.

RISK The only study-related procedure is application of non-invasive skin sensors and a brief ultrasound examination. The anticipated risk is limited to mild transient skin irritation at the sensor site, and the study is therefore considered to involve minimal risk.

Being tested
Near-infrared spectroscopy monitoring of erector spinae muscle and renal regional oxygen saturation
Keywords
rector spinae muscle regional oxygen saturation (ESrSO2), near-infrared spectroscopy (NIRS), regional oxygen saturation (rSO2, off-pump coronary artery bypass (OPCAB), acute kidney injury (AKI), KDIGO, area under the threshold (AUT), tissue oximetry
Medical subject headings
Acute Kidney Injury, Coronary Artery Disease, Postoperative Complications

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Near-infrared spectroscopy monitoring of erector spinae muscle and renal regional oxygen saturationDevice

    Non-invasive near-infrared spectroscopy monitoring performed for research purposes only. Before anesthetic induction, ultrasonography is used to measure the depth from the skin to the erector spinae muscle and to the renal cortex at the level of the left renal hilum. In eligible participants, disposable NIRS sensors are applied over the left erector spinae muscle and over the ipsilateral renal cortex, and regional oxygen saturation is recorded continuously from before induction until the end of surgery. The erector spinae and renal channels are masked on the display and no alarms are set, so the values are not used for clinical decision-making; data are extracted after surgery with the INVOS Analytics Tool. Cerebral regional oxygen saturation is monitored as part of standard institutional care. No blood sampling, imaging, or other test is performed in addition to routine care, and no cost is charged to participants.

Study groups in NCT07760129
Study groupRoleWhat they receive
OPCAB cohortAdults aged 19 years or older undergoing elective off-pump coronary artery bypass (OPCAB) surgery, in whom the skin-to-erector spinae muscle depth at the level of the left renal hilum measured by ultrasound before anesthetic induction is less than 2.0 cm. Erector spinae muscle, renal, and cerebral regional oxygen saturation are monitored continuously with near-infrared spectroscopy throughout surgery, and postoperative acute kidney injury is assessed for 7 days after surgery. A single cohort is enrolled; no comparison group is allocated, and the analysis compares participants who do and do not develop acute kidney injury within this cohort.
Receives: Device: Near-infrared spectroscopy monitoring of erector spinae muscle and renal regional oxygen saturation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Predictive performance (area under the receiver operating characteristic curve, AUROC) of intraoperative erector spinae muscle regional oxygen saturation (ESrSO2) variables for postoperative acute kidney injury

    Receiver operating characteristic curves are constructed for each candidate ESrSO2 variable and the AUROC values are calculated and compared in order to identify the variable with the highest predictive performance for acute kidney injury. Candidate variables are: (1) baseline ESrSO2 measured before anesthetic induction on room air; (2) intraoperative nadir ESrSO2; (3) area under the threshold (AUT), defined as the integral of the magnitude and duration of desaturation below a given threshold, for absolute values below 60%, 55%, and 50% and for values below 80% of baseline; and (4) duration under the same thresholds. AUT and duration under the threshold are calculated separately for the period before cardiac displacement and for the cardiac displacement period, which is defined as the interval from the deep pericardial stitch to heart return. All values are computed with the INVOS Analytics Tool Software. Acute kidney injury is defined according to the KDIGO criteria as an increase in

    Measured: ESrSO2 is recorded continuously from before anesthetic induction until the end of surgery (intraoperative period, up to approximately 6 hours). Acute kidney injury is assessed within 7 days after surgery.

Secondary outcomes (5)
  1. Independent and incremental predictive value of the selected ESrSO2 variable for acute kidney injury after adjustment for pre-specified established risk factors

    The ESrSO2 variable selected in the primary analysis is added as an incremental term to a pre-specified baseline risk model consisting of age, preoperative renal function (baseline estimated glomerular filtration rate or chronic kidney disease), diabetes mellitus, and hypoalbuminemia. These four covariates are fixed on the basis of clinical importance and previous OPCAB-AKI literature and are combined into a single linear predictor rather than being re-tested in this cohort; the only formally tested term is the ESrSO2 variable. Firth penalized logistic regression with bootstrap internal validation is used because of the limited number of expected events per variable. Improvement in discrimination is assessed by the difference in AUROC using the DeLong test, and clinical usefulness is explored by decision curve analysis (net benefit). This analysis is explicitly exploratory and is not intended to derive or validate a definitive prediction model.

    Measured: ESrSO2 recorded intraoperatively; acute kidney injury assessed within 7 days after surgery

  2. Comparison of the predictive performance (AUROC) for acute kidney injury among ESrSO2, cerebral rSO2, and renal rSO2

    Receiver operating characteristic curves are constructed separately for ESrSO2, cerebral rSO2, and renal rSO2 variables, and the AUROC values are calculated and compared with the DeLong test.

    Measured: All regional oxygen saturation channels recorded intraoperatively; acute kidney injury assessed within 7 days after surgery

  3. Predictive performance of the selected ESrSO2 variable for severe acute kidney injury (KDIGO stage 2 to 3)

    Severe acute kidney injury is defined as KDIGO stage 2 or 3 within 7 days after surgery, and predictive performance is assessed with the same methods as for the primary outcome.

    Measured: Within 7 days after surgery

  4. Predictive performance of the selected ESrSO2 variable for persistent acute kidney injury (lasting 48 hours or longer)

    Persistent acute kidney injury is defined as acute kidney injury lasting 48 hours or longer, and predictive performance is assessed with the same methods as for the primary outcome.

    Measured: Within 7 days after surgery

  5. Association between the selected ESrSO2 variable and major adverse kidney events at 30 days (MAKE-30) and days alive and out of hospital at 30 days (DAOH-30)

    MAKE-30 is defined as the composite of death, new renal replacement therapy, or persistent renal dysfunction within 30 days after surgery. DAOH-30 is the number of days alive and out of hospital during the 30 days after surgery.

    Measured: Within 30 days after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Aug 2026
  2. Study start1 Oct 2026 (estimated)
  3. Primary completion31 Oct 2029 (estimated)
  4. Study completion31 Dec 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
138 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07760129
Sponsor's protocol ID
4-2026-0845
Status last verified
Aug 2026
First submitted
6 Aug 2026
Last updated
12 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Kidney Injury and Coronary Artery Disease, run by Yonsei University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 12 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Seo Hee Ko, Professor (+82-2-2095-9678, shk0207@yuhs.ac), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Predictive performance (area under the receiver operating characteristic curve, AUROC) of intraoperative erector spinae muscle regional oxygen saturation (ESrSO2) variables for postoperative acute kidney injury (time frame: ESrSO2 is recorded continuously from before anesthetic induction until the end of surgery (intraoperative period, up to approximately 6 hours). Acute kidney injury is assessed within 7 days after surgery.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in